Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer

Journal of Cellular Biochemistry

Volumn 94, Issue 6, 2005, Pages 1069-1077

  Plate, Janet M D ^a   Harris, Jules E ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Immune effectors; Immune suppression; Immune surveillance; Mutations; Pancreas

Indexed keywords

GENE PRODUCT;

CANCER IMMUNOTHERAPY; CELL ADHESION; CELL PROLIFERATION; GENE EXPRESSION; GENE MUTATION; IMMUNE SYSTEM; MICROENVIRONMENT; MITOSIS INHIBITION; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

HUMANS; IMMUNOTHERAPY; MUTATION; PANCREATIC NEOPLASMS;

EID: 26444444723     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20378     Document Type: Review

References (55)

1. Arvanitakis M, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, Deviere J. 2004. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy 36:535-542.
2. Barnd DL, Lan MS, Metzgar RS, Finn OJ. 1989. Specific, MHC-unrestricted recognition of tumor associated mucins by human cytotoxic T cells. Proc Natl Acad Sci 86:7159-7163.
3. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. 1998. Progression of pancreatic intraductal neoplasiasto infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 22:163-169.
4. Compte E, Pontarotti P, Collette Y, Lopez M, Olive D. 2004. Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J Immunol 34:2089-2099.
5. Cowgill SM, Muscarella P. 2003. The genetics of pancreatic cancer. Am J Surg 186:279-286.
6. Day JD, Digiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, Goodman SN, Kern SE, Hruban RH. 1996. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 27:119-124.
7. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM. 1995. MUC1 epithelial tmor mucin-based immunity and cancer vaccines. Immunol Review 145:61-90.
8. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034.
9. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, Yeo CJ, Hruban RH, Goggins M. 2002. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160:1573-1581.
10. Gendler S, Taylor-Papadimitriou J, Dubig T, Rothbard J, Burchell J. 1988. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820-12825.
11. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, Thorsby E, Gaudernack G. 1995. Vaccination with mutant ras peptides and induction of T cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346:1399-1400.
12. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. 2001. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441-450.
13. Goggins M, Hruban RH, Kern SE. 2000. BRCA2 is inactivated late in the development of pancreatic intra-epithelial neoplasia: Evidence and implications. Am J Pathol 156:1767-1771.
14. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. 1996. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298-304.
15. Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD. 2004. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. MoI Cancer Ther 3:641-646.
16. Groh V, Wu J, Yee C, Spies T. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738.
17. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE. 1996. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56:490-494.
18. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. 2000. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 165:3730-3741.
19. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. 1993. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554.
20. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, Luttges J, Offerhaus GJ. 2001. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579-586.
21. Iacobuzio-Donahue CA, Wilentz RE, Argani P, Yeo CJ, Cameron JL, Kern SE, Hruban RH. 2000. Dpc4 protein in mucinous cystic neoplasms of the pancreas: Frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 24:1544-1548.
22. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. 2003a. Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63:8614-8622.
23. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M. 2003b. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162:1151-1162.
24. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. 2004. Missense mutations of MADH4: Characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 10:1597-1604.
25. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-Ll blockade. Proc Natl Acad Sci USA 99:12293-12297.
26. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ. 2001. Novel allogeneic granulocyte- macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 19:145-156.
27. Jaffee EM, Hruban RH, Canto M, Kern SE. 2002. Focus on pancreas cancer. Cancer Cell 2:25-28.
28. Janeway CA Jr, Medzhitov R. 2002. Innate immune recognition. Annu Rev Immunol 20:197-216.
29. Kalady MF, Onaitis MW, Emani S, Abdul-Wahab Z, Pruitt SK, Tyler DS. 2004. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J Gastrointest Surg 8:175-181; Discussion 181-182.
30. Leibson PJ. 2004. The regulation of lymphocyte activation by inhibitory receptors. Curr Opin Immunol 16:328-336.
31. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
32. Moskaluk CA, Hruban RH, Kern SE. 1997. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140-2143.
33. O'Dwyer ME, Druker BJ. 2000. STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 1:207-211.
34. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
35. Peiper M, Goedegebuure PS, Linehan DC, Ganguly EK, Douville CC, Eberlein TJ. 1997. The HER2/new-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Europ J Immunol 27:1115-1123.
36. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. 2004. Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep 6:199-206.
37. Plate JM, Harris JE. 2000. Immune cell functions in pancreatic cancer. Crit Rev Immunol 20:375-392.
38. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ. 2004. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother (in press).
39. Real FX. 2003. A "catastrophic hypothesis" for pancreas cancer progression. Gastroenterology 124:1958-1964.
40. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
41. Rosenberg SA, Dudley ME. 2004. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101:14639-14645.
42. Rosty C, Geradts J, Sato N, Wilentz RE, Roberts H, Sohn T, Cameron JL, Yeo CJ, Hruban RH, Goggins M. 2003. p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 27:1495-1501.
43. Satoh K, Shimosegawa T, Masamune A, Hirota M, Koizumi M, Toyota T. 1999. Fas ligand is frequently expressed in human pancreatic duct cell carcinoma. Pancreas 19:339-345.
44. Sell S. 2004. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51:1-28.
45. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828.
46. Tamura H, Ogata K, Dong H, Chen L. 2003. Immunology of B7-H1 and its roles in human diseases. Int J Hematol 78:321-328.
47. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. 2003. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856.
48. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real FX, Garrido F. 1996. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. 47:372-381.
49. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, de Villalonga P, Agell N, Lluis F, Bachs O, Capella G. 1998. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 17:1969-1978.
50. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ. 1999. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125:73-84.
51. Westra WH, Sturm P, Drillenburg P, Choti MA, Klimstra DS, Albores-Saavedra J, Montag A, Offerhaus GJ, Hruban RH. 1998. K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: Genetic evidence to support origin from the duct epithelium. Am J Surg Pathol 22:1247-1254.
52. Whiteside TL. 2004. Down-regulation of zeta-chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865-878.
53. Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH. 1998. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res 58:4740-4744.
54. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH. 2000. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60:2002-2006.
55. Xiong HQ. 2004. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54:S69-S77.